Global Community

SPX Technologies sits in a sweet spot of the fast-changing data-center world, as liquid cooling shifts spending from big chillers toward simpler outdoor heat-removal equipment. But a closer look shows parts of the business are slowing, recent deal-making adds complexity, and the stock price already assumes a lot goes right.Read more

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Workday’s shares keep sliding even as customer commitments grow and more companies turn on its built-in AI tools, suggesting the fear around “AI replacing HR software” may be overdone. The real question is whether those AI tools become an add-on that deepens customer relationships or start to replace the core product.Read more

Lincoln Minerals is a tiny Australian explorer betting on a potentially large copper find on South Australia’s remote Eyre Peninsula, where past drilling has already hinted at a bigger system. The catch is funding: recent drilling ran into setbacks, and the company may need to sell other assets to keep the copper push moving.Read more

Oscar Health looks wildly underappreciated compared with what its business could be worth, even after baking in cautious expectations. The story hinges on fast growth, strong cash generation, and a sturdy balance sheet—along with a few key assumptions that could quickly change the picture if they slip.Read more

Southern Silver is betting on the price of silver rising, aiming to sell or partner its big Mexican mine project when the market turns. With a management team that has sold a similar project before and heavy insider ownership, the upside could be large—but it depends on metal prices and patience.Read more

🪥Business Overview Key Metrics Total: 9.5/17 +2 ✅ Projected Operating Margin: 21.00% +0 ⚠️ Projected 5-Year Revenue CAGR: 3.00% +1 ✅ Last 5-Year ROIC: 16.84% +1 ✅ Estimated Cost of Capital: 8.32% (less than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.88% -1 ❌ Projected 5-Year EPS CAGR: 2.56% (given the ease of manipulating earnings metrics, sub-10% growth warrants caution) +0 ⚠️ Projected 5-Year Dividend CAGR: 4.69% +1.5 ✅ Moody's Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide +2 ✅✅ Morningstar Uncertainty: Low Procter & Gamble operates within a very competitive environment. However, its higher operating margins and wide moat its a clear sign it still operates with competitive advantages over its competitors as well as it has the capability of raising prices if needed.Read more

In a nutshell: Hims & Hers has invested heavily and benefits are starting to show through growth and expansion. Investing continues with steps taken with a clear long term goal on the background, to be a front door for customers, the delivery channel, the platform and ecosystem.Read more

A company that looks wildly cheap on paper may be flashing a danger sign, with reports in German media alleging unpaid obligations, pulled bank support, and legal threats toward critics. If you’re tempted by the glossy numbers, this is a reminder to ask whether the story holds up before you commit money.Read more